{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:44:12Z","timestamp":1772754252611,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000403","name":"Meningitis Research Foundation","doi-asserted-by":"publisher","award":["1702"],"award-info":[{"award-number":["1702"]}],"id":[{"id":"10.13039\/501100000403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3494-1","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T10:50:42Z","timestamp":1564483842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-7816","authenticated-orcid":false,"given":"Kimberly","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Craik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ushma","family":"Galal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine S.","family":"Rollier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"3494_CR1","unstructured":"Laboratory confirmed cases of invasive meningococcal infection (England): January to March 2018. Public Health England; https:\/\/www.gov.uk\/government\/publications\/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales ."},{"issue":"9","key":"3494_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","volume":"22","author":"J Bruge","year":"2004","unstructured":"Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine. 2004;22(9):1087\u201396.","journal-title":"Vaccine."},{"key":"3494_CR3","unstructured":"Joint Committee on Vaccination and Immunisation Minute of the meeting on Tuesday 11 and Wednesday 12 February 2014. 2014. https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/229171703722 . Accessed 10 May 2019."},{"key":"3494_CR4","unstructured":"Meningococcal B vaccine: JCVI position statement 2019. Public Health England. https:\/\/www.gov.uk\/government\/publications\/meningococcal-b-vaccine-jcvi-position-statement . Accessed 10 May 2019."},{"issue":"1","key":"3494_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2051013616681365","volume":"5","author":"A Banzhoff","year":"2017","unstructured":"Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5(1):3\u201314.","journal-title":"Ther Adv Vaccines"},{"issue":"2","key":"3494_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","volume":"59","author":"SI Pelton","year":"2016","unstructured":"Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2, Supplement):S3\u2013S11.","journal-title":"J Adolesc Health"},{"issue":"10","key":"3494_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","volume":"51","author":"J Findlow","year":"2010","unstructured":"Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127\u201337.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"3494_CR8","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1503\/cmaj.130257","volume":"185","author":"MD Snape","year":"2013","unstructured":"Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185(15):E715\u201324.","journal-title":"CMAJ."},{"issue":"11","key":"3494_CR9","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","volume":"29","author":"MD Snape","year":"2010","unstructured":"Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"3494_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","volume":"32","author":"MD Snape","year":"2013","unstructured":"Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013;32(10):1116\u201321.","journal-title":"Pediatr Infect Dis J"},{"key":"3494_CR11","unstructured":"Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe - - (eMC) 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/28407\/SPC\/Bexsero+Meningococcal+Group+B+vaccine+for+injection+in+pre-filled+syringe\/ . Accessed 10 May 2019."},{"issue":"5","key":"3494_CR12","doi-asserted-by":"publisher","first-page":"e01625","DOI":"10.1128\/mBio.01625-14","volume":"5","author":"I Costa","year":"2014","unstructured":"Costa I, Pajon R, Granoff DM. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio. 2014;5(5):e01625\u201314.","journal-title":"mBio."},{"issue":"10061","key":"3494_CR13","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","volume":"388","author":"SR Parikh","year":"2016","unstructured":"Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775\u201382.","journal-title":"Lancet"},{"issue":"10061","key":"3494_CR14","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/S0140-6736(16)32061-X","volume":"388","author":"NE Basta","year":"2016","unstructured":"Basta NE, Christensen H. 4CMenB vaccine effectiveness: reasons for optimism. Lancet. 2016;388(10061):2719\u201321.","journal-title":"Lancet"},{"key":"3494_CR15","unstructured":"Archived Petition: Give the Meningitis B vaccine to ALL children, not just newborn babies.: @hocpetitions; 2019. https:\/\/petition.parliament.uk\/archived\/petitions\/108072 . Accessed 10 May 2019."},{"issue":"36","key":"3494_CR16","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","volume":"33","author":"T Nolan","year":"2015","unstructured":"Nolan T, O'Ryan M, Wassil J, Abitbol V, Dull P. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine. 2015;33(36):4437\u201345.","journal-title":"Vaccine."},{"issue":"9816","key":"3494_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617\u201324.","journal-title":"Lancet"},{"issue":"39","key":"3494_CR18","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","volume":"33","author":"KP Perrett","year":"2015","unstructured":"Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217\u201324.","journal-title":"Vaccine."},{"issue":"5","key":"3494_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1542\/peds.2014-4015","volume":"135","author":"LA McNamara","year":"2015","unstructured":"McNamara LA, Shumate AM, Johnsen P, MacNeil JR, Patel M, Bhavsar T, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135(5):798\u2013804.","journal-title":"Pediatrics."},{"issue":"1","key":"3494_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1517\/14712598.2015.983897","volume":"15","author":"CS Rollier","year":"2015","unstructured":"Rollier CS, Dold C, Marsay L, Sadarangani M, Pollard AJ. The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy. Expert Opin Biol Ther. 2015;15(1):131\u201342.","journal-title":"Expert Opin Biol Ther"},{"key":"3494_CR21","unstructured":"Be on the TEAM: Teenagers Against Meningitis: ISRCTN registry. 2019. http:\/\/www.isrctn.com\/ISRCTN75858406 . Accessed 10 May 2019."},{"key":"3494_CR22","unstructured":"South Australian Meningococcal B Vaccine Herd Immunity Study - Full Text View - ClinicalTrials.gov. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03089086 . Accessed 10 May 2019."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3494-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3494-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3494-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T21:09:16Z","timestamp":1664053756000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3494-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3494-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"10 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial has been approved by Nottingham 2 Research Ethics Committee (reference 17\/EM\/0466). Informed consent will be obtained from parents\/guardians of participants and informed assent obtained from all participants in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJP reports grants from Okairos, and Pfizer, which finished within the past 36\u2009months outside the submitted work. AJP is Chair of UK Dept. Health\u2019s Joint Committee on Vaccination & Immunisation & the EMA scientific advisory group, on vaccines and is a member of the WHO\u2019s SAGE.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"455"}}